Transcription of CEFTRIAXONE-AFT - Medsafe
{{id}} {{{paragraph}}}
Example: dental hygienist
CEFTRIAXONE-AFT - Medsafe
Page 1 of 15 NEW ZEALAND DATA SHEET 1. CEFTRIAXONE-AFT powder for injection CEFTRIAXONE-AFT 500 mg powder for injection. CEFTRIAXONE-AFT 1 g powder for injection. CEFTRIAXONE-AFT 2 g powder for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTRIAXONE-AFT 500 mg: each vial contains 500 mg ceftriaxone (as sodium). CEFTRIAXONE-AFT 1 g: each vial contains 1 g ceftriaxone (as sodium). CEFTRIAXONE-AFT 2 g: each vial contains 2 g ceftriaxone (as sodium). Excipients with known effect: Each gram of ceftriaxone contains approximately 83 mg ( mmol) of sodium. 3. PHARMACEUTICAL FORM Powder for injection. White to pale yellow powder. 4. CLINICAL PARTICULARS Therapeutic indications Infections caused by pathogens sensitive to ceftriaxone : sepsis; meningitis; abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); infections of the bones, joints, soft tissue, skin and of wounds; infections in patients with impaired defence mechanisms; renal and urinary tract infections; respiratory tract infectio
CEFTRIAXONE-AFT Ceftriaxone sodium equivalent to ceftriaxone 500 mg, 1 g and 2 g powder for injection Presentation Ceftriaxone-AFT is a white to pale yellow powder packed in vials which contain the
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Considerations for Use, Negative, Aminoglycosides Staphylococcus, NEW ZEALAND DATA SHEET Curam, Cardiac Implantable Electronic Device Infection in, INFECTION CONTROL IN BURN PATIENTS, Vancomycin-Intermediate Staphylococcus, Vancomycin-Intermediate Staphylococcus epidermidis (VISE) Isolated, INFECTION CONTROL AND HOSPITAL, Infection control and hospital epidemiology